Europlasma S.A. Logo

Europlasma S.A.

ALEUP.PA

(0.5)
Stock Price

0,14 EUR

-28.9% ROA

-461.09% ROE

-1.27x PER

Market Cap.

1.005.206,00 EUR

121.49% DER

0% Yield

-110.76% NPM

Europlasma S.A. Stock Analysis

Europlasma S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Europlasma S.A. Fundamental Stock Analysis
# Analysis Rating
1 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

2 ROE

Negative ROE (-264.48%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (-28.9%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

4 PBV

The stock's elevated P/BV ratio (18.81x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 DER

The company has a high debt to equity ratio (121%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-213.190), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Europlasma S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Europlasma S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Europlasma S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Europlasma S.A. Revenue
Year Revenue Growth
2006 12.997.877
2007 29.587.295 56.07%
2008 35.297.590 16.18%
2009 31.404.000 -12.4%
2010 40.836.000 23.1%
2011 58.030.000 29.63%
2012 35.338.000 -64.21%
2013 12.572.000 -181.08%
2014 8.982.000 -39.97%
2015 14.082.000 36.22%
2016 9.733.000 -44.68%
2017 13.133.000 25.89%
2018 11.294.000 -16.28%
2019 3.154.000 -258.08%
2020 3.795.000 16.89%
2021 9.804.000 61.29%
2022 14.520.000 32.48%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Europlasma S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Europlasma S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 11.188.700
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 7.476.000 100%
2013 3.430.000 -117.96%
2014 4.342.000 21%
2015 4.483.000 3.15%
2016 4.299.000 -4.28%
2017 4.057.000 -5.96%
2018 4.770.000 14.95%
2019 2.043.000 -133.48%
2020 1.887.000 -8.27%
2021 3.621.000 47.89%
2022 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Europlasma S.A. EBITDA
Year EBITDA Growth
2006 -2.586.915
2007 2.439.725 206.03%
2008 1.389.343 -75.6%
2009 -1.565.000 188.78%
2010 4.042.000 138.72%
2011 3.698.000 -9.3%
2012 -9.518.000 138.85%
2013 -1.324.000 -618.88%
2014 -11.399.000 88.38%
2015 -9.037.000 -26.14%
2016 -10.637.000 15.04%
2017 -8.654.000 -22.91%
2018 -6.042.000 -43.23%
2019 -2.190.000 -175.89%
2020 -10.549.000 79.24%
2021 -8.860.000 -19.06%
2022 -9.872.000 10.25%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Europlasma S.A. Gross Profit
Year Gross Profit Growth
2006 13.146.057
2007 11.997.729 -9.57%
2008 11.479.823 -4.51%
2009 8.233.000 -39.44%
2010 13.943.000 40.95%
2011 8.153.000 -71.02%
2012 15.631.000 47.84%
2013 5.748.000 -171.94%
2014 2.599.000 -121.16%
2015 5.701.000 54.41%
2016 2.316.000 -146.16%
2017 7.201.000 67.84%
2018 3.066.000 -134.87%
2019 901.000 -240.29%
2020 1.619.000 44.35%
2021 5.070.000 68.07%
2022 5.712.000 11.24%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Europlasma S.A. Net Profit
Year Net Profit Growth
2006 -3.988.222
2007 -184.523 -2061.37%
2008 -1.045.917 82.36%
2009 -4.343.000 75.92%
2010 401.000 1183.04%
2011 -1.235.000 132.47%
2012 -20.891.000 94.09%
2013 -11.697.000 -78.6%
2014 -25.991.000 55%
2015 -16.163.000 -60.81%
2016 -17.345.000 6.81%
2017 -14.932.000 -16.16%
2018 -59.788.000 75.03%
2019 -12.189.000 -390.51%
2020 -8.069.000 -51.06%
2021 -12.224.000 33.99%
2022 -15.751.000 22.39%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Europlasma S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 -3.988.222
2007 -184.523 -2061.37%
2008 -1.045.917 82.36%
2009 -761 -137339.82%
2010 1.020.000 100.07%
2011 -159 645669.62%
2012 -2.661 94.06%
2013 -1.486 -79.12%
2014 -8.663.667 99.98%
2015 -5.387.667 -60.81%
2016 -3.469.000 -55.31%
2017 -2.133.143 -62.62%
2018 -4.270.571 50.05%
2019 0 0%
2020 -7.729 100%
2021 -4.077 -89.55%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Europlasma S.A. Free Cashflow
Year Free Cashflow Growth
2007 -1.221.000
2008 -3.457.000 64.68%
2009 -15.789.000 78.11%
2010 -6.031.000 -161.8%
2011 4.741.000 227.21%
2012 -15.211.000 131.17%
2013 -6.122.000 -148.46%
2014 -14.655.000 58.23%
2015 -14.271.000 -2.69%
2016 -13.339.000 -6.99%
2017 -13.822.000 3.49%
2018 -15.118.000 8.57%
2019 -1.844.750 -719.51%
2020 -16.886.000 89.08%
2021 -23.634.000 28.55%
2022 -8.042.000 -193.88%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Europlasma S.A. Operating Cashflow
Year Operating Cashflow Growth
2007 57.000
2008 378.000 84.92%
2009 -1.656.000 122.83%
2010 -369.000 -348.78%
2011 11.719.000 103.15%
2012 -7.893.000 248.47%
2013 -2.728.000 -189.33%
2014 -13.083.000 79.15%
2015 -11.996.000 -9.06%
2016 -7.754.000 -54.71%
2017 -10.730.000 27.74%
2018 -12.876.000 16.67%
2019 -1.714.000 -651.23%
2020 -12.112.000 85.85%
2021 -18.215.000 33.51%
2022 -5.139.000 -254.45%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Europlasma S.A. Capital Expenditure
Year Capital Expenditure Growth
2007 1.278.000
2008 3.835.000 66.68%
2009 14.133.000 72.86%
2010 5.662.000 -149.61%
2011 6.978.000 18.86%
2012 7.318.000 4.65%
2013 3.394.000 -115.62%
2014 1.572.000 -115.9%
2015 2.275.000 30.9%
2016 5.585.000 59.27%
2017 3.092.000 -80.63%
2018 2.242.000 -37.91%
2019 130.750 -1614.72%
2020 4.774.000 97.26%
2021 5.419.000 11.9%
2022 2.903.000 -86.67%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Europlasma S.A. Equity
Year Equity Growth
2006 25.392.417
2007 35.956.696 29.38%
2008 35.016.262 -2.69%
2009 31.404.000 -11.5%
2010 38.829.000 19.12%
2011 34.556.000 -12.37%
2012 13.808.000 -150.26%
2013 2.374.000 -481.63%
2014 16.793.000 85.86%
2015 2.495.000 -573.07%
2016 -3.640.000 168.54%
2017 -15.224.000 76.09%
2018 -40.582.000 62.49%
2019 -38.933.000 -4.24%
2020 -16.451.000 -136.66%
2021 4.474.000 467.7%
2022 5.817.000 23.09%
2023 -362.000 1706.91%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Europlasma S.A. Assets
Year Assets Growth
2006 48.216.275
2007 56.859.746 15.2%
2008 61.504.182 7.55%
2009 65.152.000 5.6%
2010 72.940.000 10.68%
2011 88.495.000 17.58%
2012 72.996.000 -21.23%
2013 48.290.000 -51.16%
2014 60.302.000 19.92%
2015 43.845.000 -37.53%
2016 42.715.000 -2.65%
2017 46.237.000 7.62%
2018 25.475.000 -81.5%
2019 19.080.000 -33.52%
2020 26.295.000 27.44%
2021 40.440.000 34.98%
2022 54.673.000 26.03%
2023 56.623.000 3.44%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Europlasma S.A. Liabilities
Year Liabilities Growth
2006 19.232.419
2007 16.938.810 -13.54%
2008 21.546.406 21.38%
2009 29.505.000 26.97%
2010 30.246.000 2.45%
2011 51.493.000 41.26%
2012 57.055.000 9.75%
2013 45.168.000 -26.32%
2014 43.381.000 -4.12%
2015 41.248.000 -5.17%
2016 46.264.000 10.84%
2017 61.430.000 24.69%
2018 66.057.000 7%
2019 58.013.000 -13.87%
2020 42.746.000 -35.72%
2021 35.966.000 -18.85%
2022 48.856.000 26.38%
2023 56.985.000 14.27%

Europlasma S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-1.27x
Price To Sales Ratio
0.07x
POCF Ratio
-3.88
PFCF Ratio
-0.12
Price to Book Ratio
3.04
EV to Sales
0.45
EV Over EBITDA
-0.66
EV to Operating CashFlow
-1.28
EV to FreeCashFlow
-0.82
Earnings Yield
-0.79
FreeCashFlow Yield
-8
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.01
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.33
ROE
-2.64
Return On Assets
-0.28
Return On Capital Employed
-0.73
Net Income per EBT
0.93
EBT Per Ebit
0.99
Ebit per Revenue
-1.2
Effective Tax Rate
0.06

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.93
Operating Profit Margin
-1.2
Pretax Profit Margin
-1.19
Net Profit Margin
-1.11

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0.56
Capex to Revenue
-0.2
Capex to Depreciation
-0.47
Return on Invested Capital
-1.01
Return on Tangible Assets
-0.29
Days Sales Outstanding
200
Days Payables Outstanding
160.5
Days of Inventory on Hand
274.62
Receivables Turnover
1.83
Payables Turnover
2.27
Inventory Turnover
1.33
Capex per Share
-0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
1.21
Debt to Assets
0.15
Net Debt to EBITDA
-0.56
Current Ratio
0.62
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
-0,03 Bil.
Invested Capital
1.21
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
4816500
Debt to Market Cap
7.93

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Europlasma S.A. Dividends
Year Dividends Growth

Europlasma S.A. Profile

About Europlasma S.A.

Europlasma S.A., together with its subsidiaries, engages in developing, constructing, and operating of the plasma torch system for industrial applications in France. It offers plasma solutions for gas and hazardous wastes. The company also engages in the production of renewable energy from waste and biomass; and provides asbestos waste treatment services, such as collection, transport, neutralization, and recovery services for hazardous waste. Europlasma S.A. was founded in 1992 and is based in Pessac, France.

CEO
Mr. Jérôme Garnache-Creuillot
Employee
187
Address
3-5 Allée des lumières
Pessac, 33600

Europlasma S.A. Executives & BODs

Europlasma S.A. Executives & BODs
# Name Age
1 Mr. Jérôme Garnache-Creuillot
Chief Executive Officer & Chairman
70

Europlasma S.A. Competitors

Neovacs S.A. Logo
Neovacs S.A.

ALNEV.PA

(1.5)
Gaussin SA Logo
Gaussin SA

ALGAU.PA

(0.8)
Drone Volt SA Logo
Drone Volt SA

ALDRV.PA

(1.0)
Hybrigenics SA Logo
Hybrigenics SA

ALHYG.PA

(1.8)
Visiomed Group SA Logo
Visiomed Group SA

ALVMG.PA

(0.5)